Zhang Tongshe was informed that on October 18, Nafi (Shenzhen) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Nafei Pharmaceutical") announced the completion of tens of millions of yuan Pre-A round of financing, which was exclusively invested by Kaitai Capital. The funds raised will be mainly used to establish a preclinical full-chain innovative drug and modified new drug research and development center, which can continue to develop innovative therapies based on nasal and cerebral drug delivery systems for central nervous system (CNS) diseases.
Founded in June 2019, NAFI Pharmaceutical is an integrated pharmaceutical technology company focusing on innovative drugs and improved new drugs for central nervous system (CNS) diseases. Committed to opening up new areas in the pharmaceutical industry, creating the first domestic and international leading benchmarking enterprise of "nasal and cerebral delivery innovative drugs", and providing safer and more effective treatment solutions for patients with CNS diseases. Nafi Pharmaceutical's pioneering Purenano nasal nanopharmaceutical delivery technology and an innovative drug for Parkinson's disease application have been patented for invention, and the world's first "Small Animal Intelligent Integrated Nasal Drug Delivery System (RA-IDDS®)" has won a number of patents. The anti-Parkinson's class of new drugs under investigation and a number of improved new drugs have achieved significant results in the preclinical research stage and will be submitted for clinical research soon.
Nasofid (Shanghai) Pharmaceutical Technology Co., Ltd. is a wholly-owned subsidiary of Nafi Pharmaceutical in Shanghai, established in May 2020, under the "Nafi (Shanghai) Nasal brain delivery drug transformation research institute", for compound molecules, polypeptides and other drugs that are difficult to enter the brain, it is committed to core technology research, breaking through technical barriers, and continuously developing innovative drugs and improved new drugs with high brain targeting. And under the guidance of industry demand, we will actively build a nafi (Shanghai) nasal brain delivery drug research and development and transformation cluster platform with preclinical full chain functions.
On behalf of Nafi Pharmaceutical, Dr. Liu Jingyi, the founder of the company, sincerely thanked the investors for their recognition and support for the company's development prospects. And believes that this round of financing will greatly help the company to accelerate the pace of research and development of innovative pharmaceuticals. She said that Nafi Pharmaceutical will always take the unmet clinical needs of "nasal brain targeting" as the innovation direction, based on scientific concepts and independent advanced technologies, give full play to the company's multidisciplinary interdisciplinary nasal brain delivery drug delivery system new technology, preparation new technology, pilot production transformation and highly innovative pharmaceutical device combination product detection and other full-chain technology cluster platform advantages, leading the innovative therapy of CNS diseases, committed to the development and application of nasal brain delivery innovative drugs and improved new drugs, providing more secure for CNS disease patients. Effective and innovative treatment options. In addition, Nafi's biomedical engineering team is developing a precision olfactory zone targeted injection delivery technology (TDI), which is expected to significantly enhance the olfactory zone target injection capability and provide greater adaptability and safety. Through the combination of drug-TDI, the brain targeting of drugs can be enhanced, the treatment of a range of brain diseases can be better treated, and systemic side effects can be reduced. The company's existing pipeline for Parkinson's disease, major depressive disorder, pain and cerebrovascular accident and other indications, are currently in the pre-clinical research stage, of which the fastest pipeline is expected to be reported for clinical studies in China and the United States in 2022.
Kaitai Capital has invested in nearly 100 biomedical and life science enterprises at home and abroad in the field of biomedicine and life sciences with a global vision, forward-looking industry research and industrial ecological investment concept, and initially formed an ecological industrial chain.
Huang Zehua, partner of Kaitai Capital, said: "The new protein-promoting autophagic degradation molecule developed by Nafi Pharmaceutical for Parkinson's patients has novel targets and mechanisms, and its carrier-free self-assembled nanoparticle delivery system has no risk of accumulation, and it is administered intranasally through the nasal brain pathway that Nafi Pharmaceutical is good at, achieving a very high brain targeted distribution. We believe that in the future, Nafi Pharma will rely on its precision nose-brain drug delivery device and the PurenanoTM nanoparticle delivery system to achieve new breakthroughs in the field of CNS disease treatment."